Groundbreaking research is expanding the frontiers of immunotherapy and molecular oncology. Novel bispecific antibodies targeting tumor-specific antigens, such as EGFRxLGR5, show therapeutic promise in solid tumors and head and neck cancers. Additionally, immunomodulatory approaches include biomimetic gels replicating adipose tissue properties to modulate ovarian cancer invasiveness and TLR7/8 agonist delivery scaffolds demonstrating efficacy against glioblastoma. These studies uncover critical cellular and molecular mechanisms, offering expanded opportunities for next-generation targeted therapies in oncology.